Therefore, we performed a meta-analysis of both randomised controlled trials (RCTs) and observational studies to compare the odds for major CV and thromboembolic events in RA patients treated with JAK inhibitors and TNF-alpha inhibitors. This evidence concerns the gene TNF and rheumatoid arthritis.